Norbert Bischofberger (Kronos)

Kro­nos seals pact with reg­u­la­tors to hunt AML with pre­vi­ous­ly off-lim­its bio­mark­er end­point

As head of R&D at Gilead, Nor­bert Bischof­berg­er shelved the SYK in­hibitor en­tosple­tinib af­ter it proved to need too lengthy a de­vel­op­ment cy­cle to win …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.